Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings on "Follow-On Biopharmac

 
 
 
 
 
 
 
 
/
 
 

More from this user

Report this document

Description:

Statement of Inger Mollerup, MSc Vice President Novo Nordisk A/S Before the Government Oversight and Reform Committee Hearing On "Safe and Affordable Biotech Drugs - The Need for a Generic Pa...